Why the study?
Although the relationship between cancers and thromboembolic events is well established, the study aimed to determine the burden of thromboembolic events in solid tumor patients and identify associated risk factors.
Answers are grounded in this paper and cite their sources.
Thromboembolism remains common in solid tumors; hypothesis-generating for risk factors, requiring prospective validation before guiding practice.
Background: The relationship between cancers and thromboembolic events is well established. In our study we aim to determine the burden of thromboembolic events in patients with solid tumors and identify the risk factors related to their development. Methods: Data on patients with solid tumors and thromboembolism between January 2013 and September 2014 were collected and analyzed. Results: During the studied period 174 patients were identified, 172 (98.9%) of which had venous thrombus embolism. 137 (79%) were diagnosed with deep vein thromboses and 67 (38.5%) with pulmonary embolisms. 84 (48.3%) were symptomatic and 90 (51.7) were incidental at diagnosis. The most common risk factors were female sex, high Body mass index, metastatic stage, colorectal and breast primaries, and anti-neoplastic therapy. Conclusion: Our study confirmed the high burden of thromboembolic events in cancer patients and the relevant risk factors associated with its development .
No takes yet. Share an insight, caveat, or question.
Bazarbashi et al. (2021) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: